Receives U.S. FDA Approval for Rituximab Biosimilar - Dr Reddys Laboratories Ltd

Code BSE: 500124 NSE:

Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar The product was developed, manufactured and submitted for approval by Dr. Reddy's Laboratories. The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company's biologics manufacturing facility in Bachupally, Hyderabad, and reflects the company's capabilities in bringing complex biologic medicines to highly regulated markets and its long-standing commitment to biosimilars. Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States, one of the world's most important pharmaceutical markets.